Yuko Iraha, Presenter: Nothing to Disclose

Masahiro Okada MD, Abstract Co-Author: Nothing to Disclose

KIMEI AZAMA, Abstract Co-Author: Nothing to Disclose

Gyou IIda, Abstract Co-Author: Nothing to Disclose

Rin Iraha, Abstract Co-Author: Nothing to Disclose

Sadayuki Murayama MD, PhD, Abstract Co-Author: Nothing to Disclose

Itaru Chiba, Abstract Co-Author: Nothing to Disclose

1. To recognize the uptake pattern of FDG in gynecological PET-CT. 2. To understand optimal planning for radiation therapy of uterine cervical cancer by using fusion of PET and MRI. 3. To understand the pitfalls of gynecological PET-CT and MRI.

1. Anatomy of uterus, ovary and other intrapelvic organs. 2. Differentiation between malignant and benign ovarian tumor using MRI and PET-CT   A) Importance of the preoperative diagnosis of ovarian tumor   B) How can the PET-CT play a role for the differential diagnosis of ovarian tumor in addition to MRI? 3. Usefulness of PET-CT for determination of cancer staging and therapeutic response   A) 3D reconstruction of PET-CT and MRI   B) Ovarian cancer and other adnexal malignancies   C) Uterine cervical cancer   D) Uterine corpus cancer 4. Pitfalls and coping technique in pelvic PET-CT and MRI   A) MRI artifacts   B) Physiological FDG uptake in the female reproductive tract   C) Uterine fibroid uptake   D) Misreading of ureteral uptake of FDG; Is it LN metastasis or not?   E) Physiologic bowel activity   F) Attenuation correction and misregistration   G) How to overcome the pitfalls of PET-CT and MRI 5. Image-guided radiotherapy for uterine cervical cancer  

http://abstract.rsna.org/uploads/2014/14004781/14004781_2k6a.pdf

Iraha, Y, Okada, M, AZAMA, K, IIda, G, Iraha, R, Murayama, S, Chiba, I, Value of PET-CT for Gynecological Tumor in Addition to MRI.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004781.html